Firs

t N

ame

Mid

dle

Initi

al

Last

Nam

e

❏ P

hysi

cian

❏

Fel

low

❏

PA

-C

❏

Nur

se

❏

NP

❏

PhD

❏

Pha

rmac

ist

❏

Indu

stry

Cre

dent

ials

Mai

ling

Addr

ess

City

Prov

/St

ate

Cou

ntry

Post

al/

Zip

Cod

e

E-m

ail (

Your

con

firm

atio

n w

ill b

e se

nt v

ia e

-mai

l)

Phon

e

Fax

Spec

ialty

Birt

h D

ate

(MM

/D

D/

YYYY

)

Inst

itute

/O

rgan

izat

ion

Paym

ent

can

be m

ade

by: ❏

Che

ck

❏

VIS

A

❏

Mas

terC

ard

❏

Dis

cove

r

❏ A

mer

ican

Exp

ress

Cha

rge

Amou

nt

Car

d N

umbe

r

Expi

ratio

n D

ate

Nam

e as

It A

ppea

rs o

n C

redi

t C

ard

Se

curit

y C

ode

Billi

ng A

ddre

ss o

f Car

d (if

diff

eren

t fr

om a

bove

; zip

cod

e re

quire

d)

Sign

atur

e

9th

Annu

al I

nter

natio

nal S

ympo

sium

on

Ovar

ian

Canc

er a

nd G

ynec

olog

ic M

alig

nanc

ies®

RE

GIS

TR

AT

ION

Prac

tice

Set

ting

:

❏ A

cade

mic

med

ical

cen

ter/

univ

ersi

ty

❏ L

abor

ator

y/ba

sic

rese

arch

❏

Pha

rmac

y

❏ C

omm

unity

hos

pita

l-bas

ed p

ract

ice

❏ G

over

nmen

t ag

ency

❏ C

omm

unity

off

ice-

base

d pr

actic

e ❏

Pha

rmac

eutic

al/

biot

echn

olog

y co

mpa

ny

❏ In

tra

inin

g (fe

llow

, res

iden

t, st

uden

t)

❏ O

ther

Wha

t is

you

r pr

inci

pal a

ctiv

ity?

❏ P

atie

nt c

are

❏

Clin

ical

res

earc

h

❏ T

each

ing/

trai

ning

❏

Adm

inis

trat

ive

❏

Oth

er

Pref

erre

d ed

ucat

iona

l for

mat

s:

❏ L

ive

❏

Onl

ine

❏

Prin

t

Pref

erre

d m

etho

ds o

f com

mun

icat

ion:

❏ P

hone

❏

Mai

l ❏

E-m

ail

Wou

ld y

ou li

ke t

o pa

rtic

ipat

e in

CM

E su

rvey

s? ❏

Yes

❏ N

o

How

man

y ca

ncer

pat

ient

s do

you

tre

at e

ach

mon

th?

Year

s pr

actic

ing

med

icin

e

Plea

se c

heck

the

app

ropr

iate

cat

egor

y:

Adv

ance

On-

Site

❏ P

hysi

cian

s$1

29$1

79

❏ N

urse

s, P

As, o

ther

$79

$129

❏ F

ello

ws

$79

$129

❏ In

dust

ry**

$259

$299

*FEL

LOW

S re

gist

ratio

n m

ust

be a

ccom

pani

ed b

y a

lett

er f

rom

you

r di

rect

or/

chai

r st

atin

g cu

rren

t fe

llow

ship

for

disc

ount

. C

anno

t be

com

bine

d w

ith o

ther

dis

coun

ts/

coup

on c

odes

. **

IND

UST

RY is

def

ined

by

PER

as a

ny p

erso

n em

ploy

ed b

y a

for-

prof

it or

gani

zatio

n, in

clud

ing

biot

ech,

fina

ncia

l, an

d ph

arm

aceu

tical

.

A c

ance

llatio

n fe

e of

25%

will

be

asse

ssed

on

refu

nds

requ

este

d pr

ior

to S

epte

mbe

r 13

, 201

3, a

nd a

50%

fee

on r

efun

ds r

eque

sted

on

Sep

tem

ber

14, 2

013,

thr

ough

Sep

tem

ber

27, 2

013.

No

refu

nds

will

be

mad

e af

ter

Sept

embe

r 28

, 201

3. T

here

is n

o ch

arge

for

subs

titut

ion.

Sub

stit

utio

ns c

an o

nly

be a

pplie

d to

the

sa

me

conf

eren

ce a

nd o

nly

two

subs

titu

tion

s w

ill b

e ho

nore

d. I

n th

e ev

ent

of a

mee

ting

canc

ella

tion,

ful

l ref

unds

will

be

proc

esse

d w

ithin

30

days

of

the

canc

ella

tion

date

.

For

regi

stra

tion

assi

stan

ce, p

leas

e e-

mai

l inf

o@go

tope

r.com

, cal

l (88

8) 9

49-0

045,

or

visi

t go

tope

r.com

.

Regi

stra

tion

fees

incl

ude

cont

inen

tal b

reak

fast

, bre

aks,

and

lunc

h.

Plea

se c

ompl

ete

the

form

to

the

left

, and

mai

l it

with

you

r pa

ymen

t (c

heck

s an

d cr

edit

card

s ar

e ac

cept

ed) t

o th

e ad

dres

s be

low

. To

regi

ster

by

phon

e or

fax,

ple

ase

call

(888

) 949

-004

5 or

fax

(609

) 257

-070

5 (c

redi

t ca

rds

only

).

Plea

se m

ake

chec

ks p

ayab

le t

o Ph

ysic

ians

’ Edu

catio

n Re

sour

ce®,

LLC

- IO

G13

.

All p

aym

ents

mus

t be

mad

e by

a d

raft

on

a U

nite

d St

ates

ban

k.

Phys

icia

ns’ E

duca

tion

Reso

urce

®, L

LC, f

ully

com

plie

s w

ith th

e le

gal r

equi

rem

ents

of t

he A

DA

and

the

rule

s an

d re

gula

tions

ther

eof.

If an

y pa

rtic

ipan

t in

this

edu

catio

nal a

ctiv

ity is

in n

eed

of

acco

mm

odat

ions

, ple

ase

notif

y us

in o

rder

to r

ecei

ve s

ervi

ce. P

leas

e ca

ll (8

88) 9

49-0

045.

Phys

icia

ns’ E

duca

tion

Reso

urce

®, L

LC66

6 Pl

ains

boro

Rd,

Ste

356

Plai

nsbo

ro, N

J 085

36

Thre

e w

ays

to r

egis

ter:

1) G

o to

our

web

site

at

goto

per.c

om

2) F

ill o

ut t

he r

egis

trat

ion

form

and

fa

x it

to (

609)

257

-070

5

(cre

dit

card

s on

ly)

3) C

all (

888)

949

-004

5

✁

Phys

icia

ns’ E

duca

tion

Reso

urce

®, L

LC66

6 Pl

ains

boro

Rd,

Ste

356

Plai

nsbo

ro, N

J 085

36

Cou

rse

Dire

ctor

s

Jam

es T

ate

Thig

pen

, MD

Pr

ofes

sor

of M

edic

ine

Dire

ctor

, Div

isio

n of

Med

ical

Onc

olog

yU

nive

rsity

of M

issi

ssip

pi S

choo

l of M

edic

ine

Jack

son,

Mis

siss

ippi

Mau

rie

Mar

kman

, MD

Seni

or V

ice

Pres

iden

t of C

linic

al A

ffai

rs &

Nat

iona

l Dire

ctor

, Med

ical

Onc

olog

yC

ance

r Tr

eatm

ent C

ente

rs o

f Am

eric

aPh

ilade

lphi

a, P

enns

ylva

nia

Mic

hael

J. B

irre

r, M

D, P

hDPr

ofes

sor,

Dep

artm

ent o

f Med

icin

eH

arva

rd M

edic

al S

choo

lD

irect

or o

f Gyn

ecol

ogic

Med

ical

Onc

olog

yM

assa

chus

etts

Gen

eral

Hos

pita

lBo

ston

, Mas

sach

uset

tsSa

turd

ay,

Oct

ob

er 5

, 20

13Lo

ews

Phila

del

phi

a H

otel

Phila

del

phi

a, P

A

Satu

rda

y, O

cto

ber

5, 2

013

Loew

s Ph

ilad

elp

hia

Hot

elPh

ilad

elp

hia

, PA

Ova

rian

Can

cer

AN

D G

YN

EC

OLO

GIC

MA

LIG

NA

NC

IES

®

INT

ER

NA

TIO

NA

L S

YM

PO

SIU

M O

N9t

h A

nnua

l

For

mor

e in

form

atio

n an

d re

gist

ratio

n, v

isit

us a

t

Ova

rian

Can

cer

AN

D G

YN

EC

OLO

GIC

MA

LIG

NA

NC

IES

®

INT

ER

NA

TIO

NA

L S

YM

PO

SIU

M O

N9t

h A

nnua

l

Act

No

w!

Regi

ster

by

Sept

embe

r 15t

h an

d sa

ve $

25!

Use

cod

e: O

13B

RO

**D

isco

unt a

vaila

ble

for p

hysi

cian

s on

ly.

For

mor

e in

form

atio

n an

d re

gist

ratio

n, v

isit

us a

t

Saturday, October 5, 2013Loews Philadelphia Hotel • Philadelphia, PA

COURSE DIRECTORS FACULTY

RECOMMENDED ACCOMMODATIONS

Loews Philadelphia Hotel1200 Market StreetPhiladelphia, PA 19107Information: (215) 627-1200Reservations: (888) 575-6397

A limited block of rooms has been set aside at Loews Philadelphia Hotel at a deluxe room rate of $179 plus applicable state and local taxes. Rates and rooms are subject to availability at the time of the reservation.

To make a reservation, call (888) 575-6397. The deadline for making your hotel reservations is September 20, 2013. After that date, or in the event that the room block becomes full prior to the deadline, rooms are subject to availability, and the room rates may increase. When booking, please mention PER Ovarian Cancer Symposium to receive the discounted group rate.

TRAVEL ARRANGEMENTSPER® recommends that you make your reservations early to get the best seat options and lowest airfare available. Philadelphia International Airport (PHL) is 9.2 miles from the hotel. Our travel partner, TraveLink, is available to assist in making travel arrangements. Please call (866) 301-3011 and ask for Peter Carson (ext. 2034) or Darrell Roberts (ext. 5193). You can also e-mail your request to Peter Carson at pcarson@trvlnk.com.

Register today and save!

SATURDAY, OCTOBER 5TH7:00 am Registration and Continental Breakfast

Morning Session

8:00 am Welcome and Framing of the Day’s EventsJames Tate Thigpen, MD

8:10 am Expert Debate #1: Patients with newly diagnosed Stage III ovarian carcinoma should undergo a laparotomy with staging and an aggressive attempt at bulk reduction prior to receiving chemotherapy.Pro: Mark A. Morgan, MD, FACOG, FACS Con: Robert Allen Burger, MD, FACOG, FACS

8:40 am Expert Debate #2: The treatment of choice for patients with newly diagnosed Stage III-IV ovarian carcinoma with bulky residual disease or with recurrent ovarian carcinoma regardless of the interval since the last chemotherapy is chemotherapy plus angiogenesis inhibitor followed by maintenance with an angiogenesis inhibitor.Pro: James Tate Thigpen, MDCon: Michael J. Birrer, MD, PhD

9:10 am Expert Debate #3: Patients with locally advanced (Stage III-IVA) endometrial carcinoma should undergo surgical resection followed by chemotherapy plus volume-directed radiation.Pro: Robert Allen Burger, MD, FACOG, FACSCon: James Tate Thigpen, MD

9:40 am Break

10:10 am Expert Debate #4: Patients with recurrent cervical carcinoma metastatic to sites outside of the pelvis should be treated with a combination of chemotherapy plus angiogenesis inhibitor.Pro: Mark A. Morgan, MD, FACOG, FACSCon: Maurie Markman, MD

10:40 am Expert Debate #5: Patients with metastatic carcinosarcoma of the uterus should be treated with a combination of ifosfamide plus paclitaxel.Pro: James Tate Thigpen, MD Con: Robert Allen Burger, MD, FACOG, FACS

11:10 am Tumor Board Discussing Cases Submitted by Audience in Advance of Conference (includes working lunch)

Afternoon Session

12:50 pm Emerging Therapies: Angiogenesis Inhibitors Robert Allen Burger, MD, FACOG, FACS

1:15 pm Emerging Therapies: PARP InhibitorsMichael J. Birrer, MD, PhD

1:40 pm Other Novel Targets and New Therapeutic Agents Russell J. Schilder, MD

2:05 pm Break

2:35 pm Update on Robotic SurgeryMark A. Morgan, MD, FACOG, FACS

3:00 pm Expert Debate #6: Genomic analysis is critical for the proper management of gynecologic cancer patients.Pro: Michael J. Birrer, MD, PhDCon: Maurie Markman, MD

3:35 pm Summary of the Day and ConclusionsMichael J. Birrer, MD, PhD

3:45 pm Adjourn

Lectures include a 5-minute Q&A session

James Tate Thigpen, MDProfessor of MedicineDirector, Division of Medical OncologyUniversity of Mississippi School of MedicineJackson, Mississippi Maurie Markman, MDSenior Vice President of Clinical Affairs &

National Director, Medical OncologyCancer Treatment Centers of AmericaPhiladelphia, Pennsylvania

Michael J. Birrer, MD, PhDProfessor, Department of MedicineHarvard Medical SchoolDirector of Gynecologic Medical OncologyMassachusetts General HospitalBoston, Massachusetts

Robert A. Burger, MD, FACOG, FACSProfessor, Department of Surgical OncologyDirector, Women’s Cancer CenterFox Chase Cancer CenterPhiladelphia, Pennsylvania

Mark A. Morgan, MD, FACOG, FACSPhiladelphia, Pennsylvania

Russell J. Schilder, MDProfessor of Medical Oncology and GynecologyJefferson Medical College of Thomas Jefferson University

Director, Gynecologic Medical OncologyKimmel Cancer Center at JeffersonPhiladelphia, Pennsylvania

Ovarian CancerAND GYNECOLOGIC MALIGNANCIES®

INTERNATIONAL SYMPOSIUM ON9th

Annual

OVERVIEW AND PURPOSEThe 9th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies® is a one-day educational and scientific meeting that will focus on key clinical topics in the management of ovarian cancer as well as endometrial, uterine, and cervical malignancies. Join our faculty of national experts as they debate and discuss the individualization of treatment plans for patients with gynecologic cancers (such as surgery, adjuvant therapy, chemotherapy, and maintenance therapy), as well as the role of robotic surgery and genomic analyses. Promising novel chemotherapeutics and targeted agents for gynecologic malignancies currently undergoing clinical trial evaluation will also be highlighted during the program. Finally, participants will have an opportunity to submit their own cases for discussion with a faculty tumor board.

TARGET AUDIENCEThis educational activity is directed toward medical oncologists and fellows who treat patients with ovarian cancer. Gynecologic oncologists, surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of ovarian cancer will be invited to participate.

LEARNING OBJECTIVES• Formulate frontline and subsequent therapy for patients based upon patient/disease

characteristics including use of surgery and adjuvant therapy• Discuss the use of first-line intraperitoneal chemotherapy for eligible patients with ovarian cancer• Describe the value of maintenance therapy for appropriate patients with ovarian cancer

following first-line chemotherapy• Assess treatment options for second-line therapy for recurrent metastatic ovarian cancer based

on sensitivity or resistance to prior platinum-based chemotherapy• Evaluate data on new agents and approaches in development for ovarian cancer• Recommend appropriate patients with ovarian cancer for clinical trial enrollment

ACCREDITATION/DESIGNATION OF CREDITPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.